Kiniksa Pharmaceuticals International (KNSA) Other financing activities (2018 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has 9 years of Other financing activities data on file, last reported at $17.6 million in Q2 2026.

• Quarterly Other financing activities rose 37.92% year-over-year to $17.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $48.8 million (up 73.98% YoY) and the FY2025 annual result came in at $40.8 million, up 136.25% from the prior year.
• Other financing activities advanced to $17.6 million in Q2 2026, from $6.4 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $17.6 million in Q2 2026 to a low of $510000.0 in Q1 2023.
• A 5-year average of $4.9 million and a median of $2.2 million in 2023 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities tumbled 78.77% — and 2025, when it soared 1022.91%.
• Tracing KNSA's Other financing activities over 5 years: stood at $1.3 million in 2022, then slipped by 25.81% to $957000.0 in 2023, then surged by 184.22% to $2.7 million in 2024, then surged by 215.29% to $8.6 million in 2025, then jumped by 104.97% to $17.6 million in 2026.
• The last three Other financing activities figures came in at $17.6 million (Q2 2026), $6.4 million (Q1 2026), and $8.6 million (Q4 2025), per Business Quant data.